Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
110.83
+0.85 (+0.77%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
June 15, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased
June 13, 2025
Jefferies thinks big pharma companies are "still on the hunt" for deals.
Via
Stocktwits
Exposures
Product Safety
1 Unpopular Stock that Deserves a Second Chance and 2 to Keep Off Your Radar
June 11, 2025
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can...
Via
StockStory
Exposures
COVID-19
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
June 02, 2025
Via
Benzinga
Why Gilead Scinces Stock Tumbled on Tuesday
June 10, 2025
Via
The Motley Fool
Exposures
Product Safety
Gelteq Stock Soars On Deal With Healthy Extracts For Product Distribution In North America: Retail Chatter Explodes
June 10, 2025
The agreement names Healthy Extracts as Gelteq’s exclusive North American storage, shipping, and fulfillment partner.
Via
Stocktwits
Exposures
Product Safety
US FDA Places Clinical Hold On Gilead Trials Of Two Investigational HIV Treatments: Retail’s On The Fence
June 10, 2025
The clinical hold is due to the identification of a safety signal, characterized by decreases in CD4+ T-cell (CD4) and absolute lymphocyte counts, in certain participants receiving the combination of...
Via
Stocktwits
Exposures
Product Safety
2 Reasons to Like GILD (and 1 Not So Much)
June 06, 2025
While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as its stock price has climbed by 21% to $111.47 per share. This performance may...
Via
StockStory
Topics
Stocks
Exposures
COVID-19
US Equities
Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
June 05, 2025
Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S. PrEP users by 2035.
Via
Benzinga
Exposures
Product Safety
1 Healthcare Stock Worth Your Attention and 2 to Turn Down
June 03, 2025
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six...
Via
StockStory
Topics
Stocks
Exposures
COVID-19
US Equities
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
June 01, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
May 31, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating
May 30, 2025
The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year.
Via
Stocktwits
Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance
May 30, 2025
Gilead Chief Commercial Officer Johanna Mercier told Reuters that the company is eyeing a “global approach" to the launch of Lenacapavir.
Via
Stocktwits
Topics
Government
Exposures
Political
Product Safety
GILEAD SCIENCES INC (NASDAQ:GILD) – A Quality Stock Worth Considering
May 30, 2025
GILEAD SCIENCES (NASDAQ:GILD) is a high-quality biopharma stock with strong profitability, efficient capital use, and attractive valuation, making it a candidate for long-term investors.
Via
Chartmill
10 Health Care Stocks Whale Activity In Today's Session
May 28, 2025
Via
Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD) – A Potentially Undervalued Biopharmaceutical Stock
May 27, 2025
GILEAD SCIENCES (NASDAQ:GILD) appears undervalued with strong profitability, a solid dividend, and reasonable growth potential, making it a candidate for value investors.
Via
Chartmill
ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
May 23, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
What Analysts Are Saying About Gilead Sciences Stock
May 21, 2025
Via
Benzinga
What's going on in today's session: S&P500 movers
May 19, 2025
Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive...
Via
Chartmill
Uncover the latest developments among S&P500 stocks in today's session.
May 19, 2025
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via
Chartmill
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
May 15, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Is the Market Bullish or Bearish on Gilead Sciences?
May 15, 2025
Via
Benzinga
Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know
May 12, 2025
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides...
Via
StockStory
Topics
Government
Stocks
World Trade
Exposures
Political
Tariff
US Equities
Top S&P500 movers in Monday's pre-market session
May 12, 2025
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
Via
Chartmill
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
May 12, 2025
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.
Via
Investor's Business Daily
Topics
Government
Stocks
Exposures
Political
US Equities
Wall Street Rips Higher As Tariff Truce Halts US–China Economic Escalation
May 12, 2025
US-China agree to slash tariffs by over 100%, easing fears of economic slowdown and inflation. Markets cheer with futures rising and yields up.
Via
Benzinga
Topics
Economy
World Trade
Exposures
Interest Rates
Tariff
GILD Q1 Earnings Call: HIV Growth and Pipeline Momentum Offset Revenue Miss
May 12, 2025
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance...
Via
StockStory
Exposures
COVID-19
Product Safety
2 High-Yield Dividend Stocks to Buy in May and Hold Forever
May 10, 2025
Via
The Motley Fool
Topics
Intellectual Property
Exposures
Intellectual Property
Market Monitor May 9 (Boeing, MicroStrategy UP - Match Group DOWN)
May 09, 2025
U.S. stocks rally amid steady Fed rates, strong Disney and AMD earnings, but Alphabet falls on Apple concerns.
Via
Chartmill
Topics
Economy
Exposures
Interest Rates
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.